Biotechnology IPOs
44 biotechnology companies tracking toward an IPO in 2026.
10x Genomics
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems at single-cell resolution. The company's technology enables researchers to study individual cells to better understand complex biological systems, disease mechanisms, and treatment responses. 10x Genomics serves the life sciences research market with applications in oncology, immunology, and neuroscience.
23andMe
23andMe is a direct-to-consumer genetic testing company that provides ancestry and health information based on DNA analysis. The company has pivoted toward drug discovery and therapeutics development, leveraging its large genetic database to attract pharmaceutical partnerships and investor interest.
Absci
Absci is a drug discovery company that uses artificial intelligence and synthetic biology to create better antibody drugs. The company's AI-driven approach to drug discovery and its partnerships with major pharmaceutical companies have positioned it as an innovative player in the biotech industry.
Alloy Therapeutics
Alloy Therapeutics is a biotechnology company that operates a drug discovery platform designed to accelerate the development of new medicines. The company partners with pharmaceutical companies and research institutions to discover and develop novel therapeutic compounds. Investors are drawn to Alloy's collaborative approach to drug discovery and its potential to generate multiple revenue streams from partnerships.
Arcturus Therapeutics
Arcturus Therapeutics is a messenger RNA medicines company focused on developing treatments for liver and respiratory diseases. The company's proprietary RNA platform and its work on both therapeutics and vaccines have attracted investor interest, particularly following increased attention to mRNA technology.
Arctus Therapeutics
Arctus Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. The company specializes in engineered cell therapies and immune system modulators designed to treat various cancer types with improved efficacy and safety profiles.
BioNTech
BioNTech is a German biotechnology company developing individualized therapies for cancer and other serious diseases using mRNA technology. The company became globally known for partnering with Pfizer to develop one of the first COVID-19 vaccines approved for emergency use.
Biosplice Therapeutics
Biosplice Therapeutics is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies for serious diseases. The company uses its splicing platform technology to develop treatments for conditions including pulmonary arterial hypertension and retinal diseases. Investors are interested in the company's novel approach to RNA therapeutics and its clinical pipeline.
Caribou Biosciences
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing programmed allogeneic cell therapies. The company focuses on off-the-shelf CAR-T and CAR-NK cell therapies for treating hematologic malignancies and solid tumors. Investors are interested in its differentiated CRISPR platform and potential to address limitations of current cell therapies.
Cellanome
Cellanome is a biotechnology company focused on single-cell genomics and multi-omics analysis platforms. The company develops tools and technologies for researchers to analyze cellular heterogeneity and understand complex biological systems at the single-cell level.
Cellarity
Cellarity is a biotechnology company that uses artificial intelligence and machine learning to analyze cellular behavior and develop new drugs. The company's platform examines how cells function as dynamic systems to identify novel therapeutic targets and accelerate drug discovery.
Codexis
Codexis is a leading enzyme engineering company that develops custom enzymes for pharmaceutical, food, and industrial applications using its proprietary CodeEvolver platform. The company's protein engineering capabilities have made it an attractive partner for major pharmaceutical companies seeking more efficient and sustainable manufacturing processes.
Color Genomics
Color Genomics provides genetic testing and telehealth services focused on hereditary cancer, heart health, and medication response. The company has built a platform combining genetic testing with clinical-grade telehealth consultations, making personalized medicine more accessible to consumers and healthcare providers.
Color Health
Color Health is a healthcare technology company that provides population health services, including genetic testing, COVID-19 testing, and health screening programs. The company partners with employers, health plans, and government agencies to deliver scalable health programs and has gained prominence for its role in COVID-19 testing infrastructure. Investors have shown interest in the company's technology-driven approach to population health management.
Colossal Biosciences
Colossal Biosciences is a biotechnology company focused on de-extinction and genetic engineering, notably working on projects to bring back extinct species like woolly mammoths. The company combines cutting-edge genetic technology with conservation efforts, attracting significant venture funding. Investors are interested in Colossal's potential applications in conservation, agriculture, and genetic medicine.
CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company developing transformative medicines using CRISPR/Cas9 technology for serious diseases. The company focuses on treatments for blood disorders, cancer, and diabetes, with advanced programs in sickle cell disease and beta-thalassemia. Investors are drawn to its clinical leadership and broad therapeutic platform.
DNAnexus
DNAnexus provides a cloud-based platform for genomic data analysis and management, serving pharmaceutical companies, research institutions, and healthcare organizations. The company offers secure, scalable infrastructure for processing large-scale genomic datasets and running bioinformatics workflows. Investors are interested in its position within the growing precision medicine and genomics market.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that uses advanced microscopy and computational biology to develop precision medicines. The company's innovative approach to drug discovery, combining cutting-edge imaging technology with AI, has attracted significant venture funding and attention from investors interested in novel drug discovery platforms.
Element Biosciences
Element Biosciences develops next-generation DNA sequencing platforms and chemistry solutions for genomics research and clinical applications. The company's AVITI sequencing system aims to provide high-quality, cost-effective sequencing with improved accuracy and workflow efficiency. Investors are interested in Element's potential to compete in the multi-billion dollar genomics market dominated by Illumina.
Enveda Biosciences
Enveda Biosciences is a biotechnology company that uses artificial intelligence and machine learning to discover new medicines from natural products. The company combines computational biology with traditional drug discovery, making it an interesting prospect for investors focused on AI-driven pharmaceutical innovation.
EQRx
EQRx was a biotechnology company focused on developing innovative medicines at radically lower prices through a new approach to drug pricing and development. The company aimed to make high-quality medicines accessible globally by reimagining the traditional pharmaceutical business model.
Formation Bio
Formation Bio is a biotechnology company that aims to accelerate drug development through AI-powered clinical trials and data analytics. The company focuses on using technology and data science to make clinical trials more efficient, cost-effective, and successful for pharmaceutical and biotech companies. Investors are interested in Formation Bio's IPO potential due to the growing intersection of AI and healthcare, particularly in drug development optimization.
Freenome
Freenome is a biotechnology company developing blood-based tests for early cancer detection using artificial intelligence and genomics. The company's platform aims to detect cancer before symptoms appear, which could significantly improve patient outcomes and represents a large market opportunity in precision medicine.
Guardant Health
Guardant Health is a precision oncology company that develops blood-based liquid biopsy tests for cancer screening and treatment. The company's flagship products include Guardant360 for advanced cancer patients and Shield for colorectal cancer screening. Investors are interested in its position in the rapidly growing liquid biopsy market and potential to transform cancer diagnostics.
Human Longevity
Human Longevity Inc. (HLI) is a genomics and precision medicine company that combines large-scale genomic sequencing with machine learning to advance health and longevity research. The company focuses on understanding human aging and developing personalized medicine approaches. Investors are interested in HLI's innovative approach to genomics and its potential in the growing precision medicine market.
Illumina
Illumina is a leading biotechnology company that develops, manufactures, and markets integrated systems for genetic analysis and DNA sequencing. The company's platforms are used in genomic research, clinical diagnostics, and applied markets including agriculture and consumer genomics. Illumina has been a key player in making DNA sequencing faster, more accurate, and cost-effective.
Immunai
Immunai is a biotechnology company that uses AI and machine learning to map and understand the immune system for drug discovery and development. The company works with pharmaceutical partners to accelerate the development of immunotherapies and precision medicine treatments. Investors are interested in Immunai's potential to revolutionize drug discovery through its computational biology platform.
Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapeutics for genetic diseases. The company focuses on both in vivo and ex vivo approaches to treat conditions like transthyretin amyloidosis and primary hyperoxaluria. Investors are attracted to its clinical progress and potential for first-in-class treatments.
Invitae
Invitae is a medical genetics company that provides genetic testing services for hereditary disorders, cancer predisposition, and other genetic conditions. The company aims to make genetic testing more accessible and affordable for patients and healthcare providers. Invitae offers comprehensive genetic testing panels and genetic counseling services to support clinical decision-making.
Isomorphic Labs
Isomorphic Labs is an AI-driven drug discovery company spun out from DeepMind, Alphabet's AI research division. The company applies advanced artificial intelligence and machine learning techniques to accelerate the discovery and development of new medicines.
Lila Sciences
Lila Sciences appears to be a life sciences or biotechnology company, though specific details about their focus area and operations have not been widely publicized. The company operates in the competitive biotech sector where investor interest often depends on specific therapeutic areas and development progress.
Mammoth Biosciences
Mammoth Biosciences is a biotechnology company that develops CRISPR-based diagnostic and therapeutic platforms. The company focuses on creating next-generation gene editing tools and diagnostic tests using its proprietary CRISPR technology, with applications in healthcare, agriculture, and industrial biotechnology. Investors are interested in Mammoth Biosciences due to the transformative potential of CRISPR technology and the company's innovative approach to gene editing applications.
Moderna
Moderna is a biotechnology company that develops messenger RNA therapeutics and vaccines to create new medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. The company gained global prominence for developing one of the first COVID-19 vaccines.
Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases including depression and other neurological disorders. The company's precision medicine approach to neuroscience and its clinical pipeline have attracted investor interest in the challenging but high-potential brain therapeutics market.
Pacific Biosciences
Pacific Biosciences (PacBio) develops and manufactures sequencing systems that enable scientists and clinical researchers to improve their understanding of the genome. The company is known for its long-read sequencing technology, which provides advantages in resolving complex genomic regions compared to short-read sequencing. PacBio's technology is used in genomics research, clinical diagnostics, and agricultural applications.
Prime Medicine
Prime Medicine is a biotechnology company developing next-generation gene editing therapies using prime editing technology. The company's platform can make precise insertions, deletions, and replacements in DNA with minimal off-target effects. Investors are attracted to its potentially superior precision compared to traditional CRISPR and its broad therapeutic applications.
Profluent Bio
Profluent Bio is a biotechnology company that uses AI and machine learning to design novel proteins and biological systems for therapeutic applications. The company focuses on developing programmable molecular tools and therapies using computational biology approaches. Investors may be interested in Profluent's position at the intersection of AI and biotechnology, two rapidly growing sectors.
Recursion Pharmaceuticals
Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery and development. The company operates one of the world's largest proprietary datasets of biological and chemical interactions to identify new therapeutic opportunities. Investors are attracted to its AI-driven approach to pharmaceutical development and potential to reduce drug discovery timelines and costs.
Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental technologies to develop targeted therapies. The company's protein motion platform and focus on oncology have positioned it as an innovative player in the precision medicine and cancer treatment space.
Tizona Therapeutics
Tizona Therapeutics is a biotechnology company focused on developing immunotherapy treatments for cancer patients. The company specializes in creating novel therapeutic approaches that harness the immune system to fight various types of cancer.
VectorBuilder
VectorBuilder provides online platform services for designing and ordering custom DNA vectors and other molecular biology tools. The company serves researchers, biotech companies, and academic institutions with synthetic biology and gene therapy research tools, operating in the growing life sciences tools market.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company developing treatments for serious infectious diseases and cancer. The company focuses on combining immunologic insights with cutting-edge technologies to develop novel therapeutics that can address global health challenges.
Wilson Wolf Corporation
Wilson Wolf Corporation develops cell culture and bioprocessing products for the biopharmaceutical industry, including specialized cell culture vessels and systems. The company serves biotechnology and pharmaceutical companies working on cell and gene therapy development. Investors may be interested in its IPO potential given the growing cell therapy market and demand for specialized manufacturing tools.
Xaira Therapeutics
Xaira Therapeutics is an AI-driven drug discovery company that uses machine learning and computational biology to accelerate pharmaceutical development. The company has attracted significant attention from investors due to its substantial funding and focus on applying artificial intelligence to streamline the traditionally lengthy and expensive drug development process.
Track Biotechnology IPOs
Get daily alerts when biotechnology companies file S-1s or announce IPO dates.
Get IPO Alerts